Filgrastim EFFECTIVENESS EVALUATION OF SOLID CANCER PATIENTS GETTING CHEMOTHERAPY IN DR. Sardjito
ABSTRACT: Neutropenia caused by chemotherapy could pose a risk of infection that causes delays in treatment and reduction of dose intensity, so it could reduce the outcome of therapy. Granulocyte colony stimulating factor (G-CSF) is clinically recommended for neutropenia and the prevention of febrile neutropenia. Filgrastim is a product of G-CSF. Filgrastim of A and B trademarks is an example of a product used in the department clinician of Dr. Sardjito. The objective of this study was to determine the time difference in reaching the absolute neutrophil count (ANC) recovery between filgrastim A and B trademarks in patients with solid cancer at Dr. Sardjito Public Hospital. This study used a retrospective cohort design. Data were taken from the medical records from January 2013-March 2015 of patients with solid cancers who were using filgrastim therapy. Data obtained by episode neutropenia, where filgrastim A total 76 episodes and filgrastim B total 70 episodes. Data were analyzed by comparing the effectiveness of filgrastim A and B trademarks with the parameter values for the ANC and ANC recovery time. The analysis was an independent sample t-test to determine differences in the increase in the value of the ANC, analysis Kapplan Meier survival curves form to observe the achievement of ANC recovery time and Chi-square to observe if the confounding variables affect the time to achieve ANC recovery. The result increased delta in ANC filgrastim A 6544,95 ± 6041,64/µL while filgrastim B 7521,54 ± 7008,15/µL, and the statistical test p value > 0,05 (0,278), so that it could be said that there was no significant difference between the increased delta in ANC filgrastim of A trademark and filgrastim B trademarks. In survival analysis using Kapplan Meier graph was gained the p value> 0,05 (0,070), this means that there was no difference between the two types of filgrastim in achieving ANC recovery. Chi-square test results among the variables of sex, age, BMI, type of cancer, the type of regimen, cycle, episode, cumulative dose and type of filgrastim with the time to achieve ANC recovery had a significant difference between grade neutropenia and the time to achieve ANC recovery of the p value <0,05 (0,015), this means that the grade neutropenia affected the time to achieve recovery.
